Enapotamab vedotin is an investigational antibody-drug conjugate (ADC) specifically targeting the receptor tyrosine kinase AXL. it consists of a monoclonal antibody linked to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) and demonstrates significant inhibitory potential against high AXL-expressing non-small cell lung cancer (NSCLC), including tumors with resistance to EGFR inhibitors like Osimertinib.
Purity:
>95.0%
CAS Number:
[1912424-97-5]
Target:
Antibody-Drug Conjugates (ADCs)|||TAM Receptor
* VAT and and shipping costs not included. Errors and price changes excepted
